Classical Hodgkin Lymphoma Latest Advances

Surprising diagnosis: classical Hodgkin lymphoma presenting as an acute asthma attack.

Journal: BMJ case reports

Published: October 14, 2025

Treatment strategy for classical Hodgkin lymphoma and future perspectives

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

The Epstein-Barr Virus in Classical Hodgkin Lymphoma: Pathogenesis, Immunobiology, and Therapeutic Implications.

Journal: Current topics in microbiology and immunology

Published: September 04, 2025

Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma.

Journal: Expert review of hematology

Published: August 06, 2025

Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.

Journal: Cancers

Published: July 14, 2025

Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.

Journal: Annals of diagnostic pathology

Published: July 05, 2025

Exploring Demographic, Prognostic, and Socioeconomic Determinants of Survival in Lymphocyte-rich Classical Hodgkin Lymphoma: A National Cancer Database Study.

Journal: Anticancer research

Published: July 01, 2025

Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy.

Journal: International journal of molecular sciences

Published: June 20, 2025

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi-Omic Analysis.

Journal: Hematological oncology

Published: June 16, 2025

Comment on “GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and Its Diagnostic Utility in Differential Diagnosis”

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 11, 2025

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials.

Journal: Frontiers in oncology

Published: May 28, 2025

Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.

Journal: British journal of haematology

Published: May 27, 2025

Filters

Surprising diagnosis: classical Hodgkin lymphoma presenting as an acute asthma attack.

Surprising diagnosis: classical Hodgkin lymphoma presenting as an acute asthma attack.

Treatment strategy for classical Hodgkin lymphoma and future perspectives

Treatment strategy for classical Hodgkin lymphoma and future perspectives

The Epstein-Barr Virus in Classical Hodgkin Lymphoma: Pathogenesis, Immunobiology, and Therapeutic Implications.

The Epstein-Barr Virus in Classical Hodgkin Lymphoma: Pathogenesis, Immunobiology, and Therapeutic Implications.

Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma.

Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma.

Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.

Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.

Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.

Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.

Exploring Demographic, Prognostic, and Socioeconomic Determinants of Survival in Lymphocyte-rich Classical Hodgkin Lymphoma: A National Cancer Database Study.

Exploring Demographic, Prognostic, and Socioeconomic Determinants of Survival in Lymphocyte-rich Classical Hodgkin Lymphoma: A National Cancer Database Study.

Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy.

Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy.

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi-Omic Analysis.

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi-Omic Analysis.

Comment on “GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and Its Diagnostic Utility in Differential Diagnosis”

Comment on “GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and Its Diagnostic Utility in Differential Diagnosis”

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials.

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials.

Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.

Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.